

The causal relationship between cathepsins and multiple sclerosis : a mendelian randomization study

1 Haining Lin¹¶, Yuqing Shi ¹& ,Huazhong Xiong²,Dongyi Wang¹, Shilei Wang¹,Hailan Kang¹,ZiXu

2 Wang¹,Zeyu Wang^{1*} and Jixiang Ren^{1,3*}

3 ¹ Changchun University of Chinese Medicine, Changchun, China

4 ² Prevention and Treatment Center,Affiliated Hospital to Changchun University of Chinese
5 Medicine , Changchun, China

6 ³First Affiliated Hospital to Changchun University of Chinese Medicine , Changchun, China

7 * Corresponding authors

8 E-mail addresses: renjx2003@163.com (J. Ren)

9 E-mail addresses: zeyu781022@163.com (Z. Wang)

10 These authors contributed equally to this work.

11

12

13

14

15

16

17

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

18 **Abstract**

19 **Background:** Multiple sclerosis (MS) is a chronic autoimmune neurodegenerative
20 disease. Although some evidence indicates the potential involvement of cathepsins in
21 the MS process, the precise nature of this involvement remains uncertain. The
22 objective of this study was to ascertain whether there is a causal relationship between
23 cathepsins and MS.

24 **Methods:** This study aimed to examine the relationship between nine cathepsins and
25 MS, incorporating heterogeneity and sensitivity analyses into the study design. The
26 MR study was reported according to the STROBE-MR checklist.

27 **Results:** The MR analysis revealed a causal relationship between cathepsin H and MS
28 (IVW: $P=0.036$, $OR=1.095$, $95\% CI=1.006-1.192$); and an inverse causal relationship
29 between cathepsin E and MS (IVW: $P=0.031$, $OR=1.043$, $95\% CI=1.004-1.083$).

30 **Conclusion:** Genetically predicted risk of developing MS was associated with
31 increased cathepsin H, whereas elevated cathepsin E was associated with developing
32 MS, and their causal relationships were both unidirectional.

33 **Keywords:** Mendelian randomization, Multiple sclerosis, Cathepsin,
34 Demyelination, Nervous system disease.

35

36

37

38 **Introduction**

39 Multiple sclerosis (MS) is a chronic inflammatory illness caused by the immune
40 system, characterized by neurodegeneration and demyelination[1].MS has the
41 potential to result in a reduction in the quality of life of those affected, with the
42 possibility of further complications such as disability. This is due to the fact that MS
43 can manifest itself in neurological symptoms.The incidence and prevalence of MS are
44 increasing annually[2].In addition to several well-defined environmental factors.
45 Furthermore, numerous genes have been identified that, to a moderate extent, increase
46 disease susceptibility.[3].Autoimmune activity against myelin components is thought
47 to be the primary process underlying the pathology of MS[4],including significant
48 infiltration of activated leukocytes into the central nervous system(CNS) via the
49 blood-brain barrier and processing and presentation of self-antigens by
50 antigen-presenting cells.[4, 5].

51 An imbalance between protein hydrolysis and protein synthesis is a key factor in the
52 development of CNS diseases. Consequently, the study of protein degradation
53 pathways is of great importance in understanding the underlying pathology of these
54 diseases[6].Cathepsins are involved in a number of cellular processes, including cell
55 signalling, autophagy, and the transformation of proteins and lipids. They are
56 primarily responsible for the metabolic degradation of peptides and proteins within
57 lysosomes[7, 8].Some evidence suggests that in patients with MS, enzymatic
58 activities of the proteasome are enhanced in the central nervous system.[9].Cathepsins
59 can be classified into three categories: cysteine cathepsins (cathepsin B, C, L, etc.),

60 serine cathepsins (cathepsin G), and aspartate cathepsins (cathepsin D and E)[10].
61 Furthermore, there is a strong correlation between the activity of tissue proteases and
62 the progression of neurodegenerative diseases[11, 12].In immune cells, cathepsin S
63 and cathepsin L play a pivotal role in the processing of antigenic peptides and the
64 presentation of antigens by histocompatibility complex class II molecules. They are
65 also involved in the progressive catabolism of integral membrane proteins, which are
66 encoded by invariant chains and are expressed on the surface of antigen-presenting
67 cells[13-15].The invasive and migratory properties of certain cathepsins [16, 17]may
68 be attributed to their capacity to maintain activity and degrade extracellular matrix
69 (ECM) components, including laminin, and collagen, at physiological pH
70 values[18].Given that protein hydrolytic degradation constitutes a pivotal process in
71 demyelination during MS, with the potential to precipitate neurodegeneration,
72 cathepsins have been demonstrated to cleave myelin basic proteins, thereby exerting a
73 pivotal role in disease progression[19].
74 In previous studies, although there is some evidence that cathepsins are involved in
75 the process of MS, there is a lack of clear causality between cathepsins and MS, we
76 used Mendelian randomisation (MR) analysis, which combines data from
77 genome-wide association studies (GWAS), is a statistical method used to determine
78 the causal relationship between exposures and outcomes[20].MR analyses have been
79 used more widely to assess possible causality between exposures and outcomes
80 because of the effectiveness of MR in reducing confounding bias and preventing
81 reverse causation, advantages that are based on the inability of the disease to alter the

82 genotypes in the germ line.

83 The goal of this study was to investigate the relationship between nine cathepsins and
84 MS, as identified through a large-scale genome-wide association study (GWAS),
85 through a comprehensive analysis of the genetic variants associated with them. This
86 was accomplished through the utilisation of a two-sample bidirectional MR approach,
87 which yielded insightful findings that significantly advanced the comprehension of
88 the underlying causal relationship between cathepsins and MS.

89 **Materials and methods**

90 **Data sources**

91 The gene detection levels of cathepsin B, E, F, G, H, L2, O, S, and Z (a total of nine
92 types of cathepsins) were obtained from the INTERVAL study. The data can be
93 accessed publicly via the following website: <https://gwas.mrcieu.ac.uk>. The sample
94 size of this study is 3,301, and the participants are of European ethnicity[21].The
95 INTERVAL study has been approved by the National Research Ethics Service in the
96 United States, with approval number 11/EE/0538.

97 The International Classification of Diseases, Eleventh Revision code (ICD-11) for MS
98 is 8A40. The disease is defined as an inflammatory demyelinating disease
99 characterised by episodic neurological dysfunction in at least two central nervous
100 system regions (brain, spinal cord, and optic nerves) at different times and in different
101 spaces (different sites of lesions). The diagnostic criteria follow the 2017 version of
102 the McDonald diagnostic criteria [22]. The GWAS data for MS were obtained from

103 the publicly available GWAS database (<https://gwas.mrcieu.ac.uk/>), GWAS number
104 ieu-b-18, which analysed the genetic data of 47,429 individuals. A total of 68,374
105 control subjects and 1,000 individuals with MS were included in the study, which
106 aimed to create a reference atlas of the genetic structure of MS in the European
107 population. The study involved both male and female subjects, and the number of
108 single-nucleotide polymorphisms (SNPs) identified was 6,304,359 [23].

109 To prevent the introduction of bias and avoid data overlap, the sample data for
110 cathepsins and MS were obtained from independent GWAS databases. No additional
111 ethical approval or licence is required for the study, as all studies undergo review and
112 approval by the relevant institutional ethics review committee and informed written
113 consent is obtained from each participant.

114 **Study design and selection of IVs**

115 The study methodology was in accordance with the STROBE-MR list [24], and we
116 conducted a two-sample bidirectional MR study using publicly available GWAS
117 summary data. The MR analyses were based on three key assumptions [25], the details
118 of which are shown in Fig. 1, and we performed MR analyses and reverse MR
119 analyses of cathepsins and MS, respectively.

120

121 **Fig1. Flowchart of MR analysis.** Three key assumptions of MR analysis: (1) IV must
122 be strictly related to the exposure factor; (2) IV must be independent of confounders
123 between the exposure factor and the outcome; and (3) IV will not influence the
124 outcome due to factors other than the exposure factor.

125

126 The following methods were employed to identify single-nucleotide polymorphisms
127 (SNPs) associated with exposure factors, with the objective of ensuring the reliability
128 and accuracy of the results. SNPs with robust associations (p-value significance
129 threshold of less than 5×10^{-6}) were treated as IVs. Additionally, those with
130 strand-balanced SNPs ($r^2 = 0.001$, genetic distance = 1000 kb) were excluded to
131 eliminate any potential bond disequilibrium[24]. To evaluate the potential for weak
132 instrumental bias, the F-statistic was employed to assess the weak IV bias of the
133 selected IVs[26].

134

135 **MR analysis**

136 The study was analysed using the TwoSampleMR (version 0.5.6) package in R
137 (version 4.4.1), and MR analyses were performed to estimate the overall effect of the
138 selected SNPs on MS. The following MR methods were employed: Egger, Weighted
139 median, Inverse variance weighted, Simple mode and Weighted mode, with the
140 objective of verifying the consistency of the results[27]. Subsequently, inverse MR
141 analysis was conducted using the aforementioned MR methods. The odd ratio (OR)
142 was found to be statistically significant at the 95% confidence level with a two-sided
143 significance test, with $P < 0.05$.

144 The MR Egger intercept was employed for the purpose of detecting horizontal
145 pleiotropy. In the event that the intercept was found to be statistically significant ($P <$
146 0.05), it was necessary to consider the reliability of the results. The Cochran's Q
147 statistic was utilised for the assessment of heterogeneity ($P < 0.05$), while funnel plots

148 were employed for the purpose of The results are illustrated. The MR-PRESSO
149 outlier test and the estimated calibration values were applied to remove horizontal
150 pleiotropy, which can be used to exclude aberrant SNPs. The generation of forest
151 plots in the study enabled a visual assessment of the robustness of the results after
152 SNP removal by the leave-one-out method.

153 **Results**

154 **IV selection**

155 The present investigation utilised genetic variants from the INTERVAL study to
156 examine cathepsins for MS from the GWAS database. Our bidirectional MR analyses
157 identified multiple SNPs as IVs for each cathepsin and MS disease status, with a
158 genome-wide significance threshold of $P < 5 \times 10^{-6}$. The F-statistic for each selected
159 IV exceeded 10, indicating no weak IV bias.

160 **Results of the main MR analyses**

161 A two-sample MR analysis was conducted to evaluate the impact of cathepsins on MS,
162 employing a range of data analysis techniques, including MR Egger, weighted median,
163 inverse variance weighted, simple mode, and weighted mode. Of these approaches,
164 the inverse variance weighted method is regarded as the most reliable for data
165 analysis, particularly in instances where directed pleiotropy is absent. This method is
166 frequently employed in meta-analyses of the effects of multiple genetic variants.

167

168 The findings of the two-sample MR analysis examining the relationship between

169 cathepsins and MS are illustrated in Figure 2. Additionally, a reverse MR analysis
170 investigating the reverse association between MS and cathepsins is presented in
171 Figure 3. All positive results ($P > 0.05$) are presented in Table 1 for the reader's
172 convenience. The analysis indicates a causal relationship between cathepsin H and
173 MS, as well as a reverse causal relationship between cathepsin E and MS. Specifically,
174 elevated cathepsin H may be associated with an increased risk of developing MS
175 (IVW: $P=0.036$, $OR=1.095$, $95\% CI=1.006-1.19$). Furthermore, elevated cathepsin E
176 may be associated with the development of MS (IVW: $P=0.031$, $OR=1.043$, 95%
177 $CI=1.004-1.083$).

178 Furthermore, the Cochran Q test was employed to ascertain the extent of
179 heterogeneity between the SNPs. No evidence of heterogeneity or pleiotropy in
180 positive causality was identified ($P > 0.05$), as evidenced by the resulting P-values and
181 MR-Egger intercepts (Table 1). The leave-one-out method analysis additionally
182 validated the robustness of the positive results, as illustrated in Figure 4.

183
184

185 **Fig2, MR results of the causal relationship between cathepsins and MS, OR, odds**
186 **ratio; CI, confidence interval.**

187

188 **Fig3, MR results of inverse causality between cathepsins and MS, OR, odds ratio;**
189 **CI, confidence interval.**

190

191

192 **Table 1 Mendelian randomisation analysis with positive results**

exposure	outcome	method	NSN P	pval	or(95%CI)	Cochran Q test		MR Egger		
						Q-value	P-value	Intercept	P-value	
cathepsin H	multiple sclerosis	MR Egger	14	0.643	0.944(0.744-1.198)	16.484	0.170	0.028	0.217	
		Weighted median	14	0.001	1.198(1.082-1.327)					
		Inverse variance weighted	14	0.036	1.095(1.006-1.192)					
		Simple mode	14	0.091	1.204(0.987-1.468)					
		Weighted mode	14	0.015	1.201(1.056-1.366)					
multiple sclerosis	cathepsin E	MR Egger	86	0.249	1.036 (0.976-1.099)	96.771	0.161	0.001	0.779	
		Weighted median	86	0.118	1.048 (0.988-1.111)					
		Inverse variance weighted	86	0.031	1.043 (1.004-1.083)					
		Simple mode	86	0.231	1.078 (0.954-1.217)					
		Weighted mode	86	0.074	1.052 (0.996-1.112)					

193

194

195 **Fig4 Scatterplot and leave-one-out analysis of Mendelian randomised causality,**

196 (a) MR analysis of cathepsin H versus MS (b) reverse MR analysis of cathepsin E

197 versus MS (c) sensitivity analysis of the leave-one-out method for cathepsin H versus

198 MS (d) sensitivity analysis of the leave-one-out method for reverse causality of

199 cathepsin E versus MS.

200 Discussion

201 MS manifests itself as an autoimmune demyelinating and neurodegenerative disease

202 of the central nervous system. The mechanism by which MS occurs has not been fully

203 elucidated, and is widely believed to be due to an autoimmune attack on

204 myelin. Genetic and environmental factors are thought to play a role in triggering the
205 immune system's attack on myelin[28]. Cathepsins are associated with the
206 development of neurodegenerative and immunocompetent disorders and are usually
207 correlated with pathological conditions [8, 29]. Evidence from relevant studies has
208 shown [30-33] that a variety of cysteine cathepsins are involved in the inflammatory
209 process of different diseases through different pathological mechanisms [34]. While
210 in autoimmune mechanisms, cathepsins play a major role in phagocytosis and
211 autophagy [35], cathepsins may exert an indirect regulatory effect on autophagy and a
212 direct influence on cellular homeostasis and inflammatory processes[36]. In addition,
213 cathepsins play an immunological role in the cytoplasmic lysosome, nucleus or
214 extracellular space, e.g. The release of cathepsins from the cytoplasmic lysosome and
215 nucleus may occur via either controlled or uncontrolled lysosomal membrane
216 permeabilisation, resulting in lysosomal-dependent cell death [37]. Conversely, those
217 present in the extracellular space may be involved in the remodelling of the
218 extracellular matrix[10]. Thus cathepsins may be involved in the disease progression
219 of MS.

220 Our findings suggest that the pathogenesis of MS may be associated with elevated
221 cathepsin H. Although there are fewer studies directly correlating cathepsin H with
222 the pathogenesis of MS, the current mechanism in animal models is thought to be that
223 defective cathepsin H impairs TLR3-mediated activation of IRF3 and the consequent
224 secretion of IFN- β by dendritic cells, leading to enhanced differentiation of Th1 cells,
225 which leads to the early onset of experimental autoimmune encephalomyelitis (EAE,

226 an animal model of multiple sclerosis)[38].However, demyelination is a characteristic
227 manifestation of MS, and myelin is essential for neuronal axonal function in the CNS,
228 whereas microglia regulate the growth and integrity of myelin in the CNS, and are
229 required to maintain myelin integrity by preventing myelin degeneration [39], and
230 microglia are immune cells residing in the brain that are involved in tissue
231 maintenance and immunosurveillance[40]. Cathepsin H was detected in different
232 brain regions within activated microglia, and a related study showed that CatH was
233 significantly upregulated in microglia from mice injected intraperitoneally with
234 lipopolysaccharide, and that pro-inflammatory cytokines induced the release of CatH
235 from microglia, with profound and deleterious effects on microglia activation and
236 neuronal survival[41].Another study showed that cathepsin H expression was
237 increased in microglia at the site of injury in a hypoxic-ischemic mouse model, and
238 that cathepsin H inhibited astrocyte proliferation by controlling TLR3/IRF3 signalling
239 and subsequent IFN- β secretion [42]. We therefore hypothesise that microglia
240 function may be a relevant mechanism for the causal relationship between cathepsin
241 H and the development of MS, however existing studies on the correlation between
242 cathepsin H and MS are insufficient.Further studies are required to gain a
243 comprehensive understanding of the relationship between the aforementioned
244 variables. The findings of the present MR analysis may serve as a valuable point of
245 reference for future investigations into the role of cathepsin H in MS.

246 In our findings, suffering from MS may lead to elevated cathepsin E. Although
247 evidence that MS directly leads to elevated cathepsin E has not emerged from current

248 research advances, it is interesting to note that related studies have suggested that
249 cathepsin E may be associated with an underlying mechanism of MS-related pain [43].
250 This study found that cathepsin E-deficient mice were resistant to mechanically
251 abnormal pain in EAE and that cathepsin E contributes to mechanically abnormal pain
252 in EAE mice, however, this study could not confirm the relationship between
253 cathepsin E and MS-related neuropathic pain, as EAE can be induced by a variety of
254 immunogenic peptides, and therefore further analyses are still required. Notably, in
255 the CNS, cathepsin E is expressed only in microglia[44], and microglia activation is a
256 key factor in the induction of mechanical abnormalities in pain[45]; Moreover,
257 cathepsin E has been demonstrated to be a crucial mediator in major
258 histocompatibility complex class II-mediated antigen presentation in microglia [46].
259 In conclusion, analysis of MR results suggests that suffering from MS may lead to
260 elevated cathepsin E, and related studies suggest that this may be associated with pain
261 in the disease; however, there are fewer available findings on cathepsin E and MS, so
262 further in-depth studies are necessary, and our results may provide potential research
263 directions for future studies on MS-related pain and cathepsin E.
264 Our findings establish a causal relationship between a range of cathepsins and MS. By
265 employing MR analysis, the data can be understood with greater reliability and
266 accuracy, avoiding potential bias introduced by external factors. MR analysis is a
267 method of analysing genetic variation. The results of the present study contribute to
268 the discovery of the role of cathepsins in the progression of MS and provide further
269 research with potential value. It is important to acknowledge the limitations of this

270 study. Firstly, it should be noted that the GWAS data used in this study were derived
271 from Europe only and therefore do not represent a generalisable sample of the wider
272 population. Consequently, further expansion of the study is still needed. Secondly,
273 there is evidence to suggest that cathepsin B may be associated with MS. A clinical
274 observational study demonstrated an increase in cathepsin B activity in peripheral
275 blood mononuclear cells of MS patients[47], while the use of cathepsin B inhibitors
276 resulted in a significant reduction in the severity of clinical scores in EAE mice
277 [48].However, despite these findings, we were unable to identify a genetic tool for the
278 cathepsin B correlation, which led to the exclusion of our results from the tissue
279 causal analyses of cathepsin B and MS. Secondly, as MR analysis can only provide
280 evidence of potential causality and is unable to identify the specific biological
281 pathways involved, future studies should combine bioinformatics analyses with
282 relevant experiments to elucidate and validate the underlying mechanisms.

283 **Conclusion**

284 This study examined scathepsins and MS using a bidirectional MR approach and the
285 findings provide suggestive evidence that genetically predicted risk of developing MS
286 is associated with increased cathepsin H and elevated cathepsin E is associated with
287 developing MS, and that they are both unidirectionally causally related, however,
288 further intervention trials are needed to elucidate the underlying mechanisms.

289 **Data availability statement**

290 The original contributions from this study are included in the article. Additional data
291 inquiries can be directed to the corresponding authors.

292 **Author contributions**

293 Haining Lin: Investigation, Data curation, Writing - original draft, Writing -
294 review & editing. Yuqing Shi: Investigation, Data curation, Methodology. Huazhong
295 Xiong: Investigation, Data curation. Dongyi Wang: Investigation, Project
296 administration. Shilei Wang: Investigation, Validation. Hailan Kang: Investigation.
297 Zixu Wang: Investigation. Zeyu Wang: Writing - review & editing. Jixiang Ren:
298 Conceptualization, Writing - review & editing.

299 **Funding**

300 This article received support from the Natural Science Foundation of Jilin Province
301 (No.YDZJ202301ZYTS184) and the Administration of Traditional Chinese Medicine
302 of Jilin Province (No.2023021).

303 **Acknowledgments**

304 The authors are thankful to all participants and investigators who contributed and
305 shared summary-level data on GWAS.

306 **Conflict of interest**

307 The authors affirm that the research was conducted without any potential conflict of
308 interest arising from commercial or financial relationships.

309 References

- 310 1. Marcus R. What Is Multiple Sclerosis? *Jama*. 2022; 328(20): 2078.
311 <https://doi.org/10.1001/jama.2022.14236> PMID: 36413229.
- 312 2. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of Multiple
313 Sclerosis 2013: A growing global problem with widespread inequity. *Neurology*. 2014; 83(11):
314 1022-1024. <https://doi.org/10.1212/wnl.0000000000000768> PMID: 25200713.
- 315 3. Dobson R, Giovannoni G. Multiple sclerosis - a review. *Eur J Neurol*. 2019; 26(1): 27-40. Epub
316 20181118. <https://doi.org/10.1111/ene.13819> PMID: 30300457.
- 317 4. Compston A, Coles A. Multiple sclerosis. *Lancet*. 2008; 372(9648): 1502-1517.
318 [https://doi.org/10.1016/s0140-6736\(08\)61620-7](https://doi.org/10.1016/s0140-6736(08)61620-7) PMID: 18970977.
- 319 5. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?
320 *Ann Neurol*. 2009; 65(3): 239-248. <https://doi.org/10.1002/ana.21640> PMID: 19334069.
- 321 6. Górska E, Tylicka M, Kamińska J, Hermanowicz A, Matuszczak E, Ołdak Ł, et al. 20S constitutive
322 proteasome, 20S immunoproteasome, and cathepsin S are high-sensitivity and independent markers
323 of immunological activity in relapsing-remitting type of multiple sclerosis. *J Neurochem*. 2024. Epub
324 20240624. <https://doi.org/10.1111/jnc.16165> PMID: 38923513.
- 325 7. Fonović M, Turk B. Cysteine cathepsins and extracellular matrix degradation. *Biochim Biophys*
326 *Acta*. 2014; 1840(8): 2560-2570. Epub 20140327. <https://doi.org/10.1016/j.bbagen.2014.03.017> PMID:
327 24680817.
- 328 8. Brix K, Dunkhorst A, Mayer K, Jordans S. Cysteine cathepsins: cellular roadmap to different
329 functions. *Biochimie*. 2008; 90(2): 194-207. Epub 20070806.
330 <https://doi.org/10.1016/j.biochi.2007.07.024> PMID: 17825974.
- 331 9. Minagar A, Ma W, Zhang X, Wang X, Zhang K, Alexander JS, et al. Plasma ubiquitin-proteasome
332 system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and
333 treatment with interferon-beta-1b. *Neurol Res*. 2012; 34(6): 611-618. Epub 20120616.
334 <https://doi.org/10.1179/1743132812y.0000000055> PMID: 22709658.
- 335 10. Vidak E, Javoršek U, Vizovišek M, Turk B. Cysteine Cathepsins and their Extracellular Roles:
336 Shaping the Microenvironment. *Cells*. 2019; 8(3). Epub 20190320.
337 <https://doi.org/10.3390/cells8030264> PMID: 30897858.
- 338 11. Ginsberg SD, Hemby SE, Lee VM, Eberwine JH, Trojanowski JQ. Expression profile of transcripts in
339 Alzheimer's disease tangle-bearing CA1 neurons. *Ann Neurol*. 2000; 48(1): 77-87. PMID: 10894219.
- 340 12. Moon HY, Becke A, Berron D, Becker B, Sah N, Benoni G, et al. Running-Induced Systemic
341 Cathepsin B Secretion Is Associated with Memory Function. *Cell Metab*. 2016; 24(2): 332-340. Epub
342 20160623. <https://doi.org/10.1016/j.cmet.2016.05.025> PMID: 27345423.
- 343 13. Burster T, Beck A, Tolosa E, Schnorrer P, Weissert R, Reich M, et al. Differential processing of
344 autoantigens in lysosomes from human monocyte-derived and peripheral blood dendritic cells. *J*
345 *Immunol*. 2005; 175(9): 5940-5949. <https://doi.org/10.4049/jimmunol.175.9.5940> PMID: 16237087.
- 346 14. Zavasnik-Bergant T, Turk B. Cysteine proteases: destruction ability versus immunomodulation
347 capacity in immune cells. *Biol Chem*. 2007; 388(11): 1141-1149. <https://doi.org/10.1515/bc.2007.144>
348 PMID: 17976006.
- 349 15. Hsing LC, Rudensky AY. The lysosomal cysteine proteases in MHC class II antigen presentation.
350 *Immunol Rev*. 2005; 207: 229-241. <https://doi.org/10.1111/j.0105-2896.2005.00310.x> PMID:
351 16181340.

- 352 **16.** Flannery T, Gibson D, Mirakhur M, McQuaid S, Greenan C, Trimble A, et al. The clinical
353 significance of cathepsin S expression in human astrocytomas. *Am J Pathol.* 2003; 163(1): 175-182.
354 [https://doi.org/10.1016/s0002-9440\(10\)63641-3](https://doi.org/10.1016/s0002-9440(10)63641-3) PMID: 12819022.
- 355 **17.** Gillet L, Roger S, Besson P, Lecaille F, Gore J, Bougnoux P, et al. Voltage-gated Sodium Channel
356 Activity Promotes Cysteine Cathepsin-dependent Invasiveness and Colony Growth of Human Cancer
357 Cells. *J Biol Chem.* 2009; 284(13): 8680-8691. Epub 20090128.
358 <https://doi.org/10.1074/jbc.M806891200> PMID: 19176528.
- 359 **18.** Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in
360 cardiovascular disease. *Faseb j.* 2007; 21(12): 3029-3041. Epub 20070523.
361 <https://doi.org/10.1096/fj.06-7924com> PMID: 17522380.
- 362 **19.** Wilkinson RD, Williams R, Scott CJ, Burden RE. Cathepsin S: therapeutic, diagnostic, and
363 prognostic potential. *Biol Chem.* 2015; 396(8): 867-882. <https://doi.org/10.1515/hsz-2015-0114> PMID:
364 25872877.
- 365 **20.** Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for
366 performing Mendelian randomization investigations: update for summer 2023. *Wellcome Open Res.*
367 2019; 4: 186. Epub 20230804. <https://doi.org/10.12688/wellcomeopenres.15555.3> PMID: 32760811.
- 368 **21.** Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of the
369 human plasma proteome. *Nature.* 2018; 558(7708): 73-79. Epub 20180606.
370 <https://doi.org/10.1038/s41586-018-0175-2> PMID: 29875488.
- 371 **22.** Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple
372 sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* 2018; 17(2): 162-173. Epub
373 20171221. [https://doi.org/10.1016/s1474-4422\(17\)30470-2](https://doi.org/10.1016/s1474-4422(17)30470-2) PMID: 29275977.
- 374 **23.** Multiple sclerosis genomic map implicates peripheral immune cells and microglia in
375 susceptibility. *Science.* 2019; 365(6460). <https://doi.org/10.1126/science.aav7188> PMID: 31604244.
- 376 **24.** Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al.
377 Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian
378 Randomization: The STROBE-MR Statement. *Jama.* 2021; 326(16): 1614-1621.
379 <https://doi.org/10.1001/jama.2021.18236> PMID: 34698778.
- 380 **25.** Gagliano Taliun SA, Evans DM. Ten simple rules for conducting a mendelian randomization study.
381 *PLoS Comput Biol.* 2021; 17(8): e1009238. Epub 20210812.
382 <https://doi.org/10.1371/journal.pcbi.1009238> PMID: 34383747.
- 383 **26.** Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization
384 studies. *Int J Epidemiol.* 2011; 40(3): 755-764. Epub 20110316. <https://doi.org/10.1093/ije/dyr036>
385 PMID: 21414999.
- 386 **27.** Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian
387 randomization analyses using summarized data. *Int J Epidemiol.* 2017; 46(6): 1734-1739.
388 <https://doi.org/10.1093/ije/dyx034> PMID: 28398548.
- 389 **28.** McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A
390 Review. *Jama.* 2021; 325(8): 765-779. <https://doi.org/10.1001/jama.2020.26858> PMID: 33620411.
- 391 **29.** Kramer L, Turk D, Turk B. The Future of Cysteine Cathepsins in Disease Management. *Trends*
392 *Pharmacol Sci.* 2017; 38(10): 873-898. Epub 20170628. <https://doi.org/10.1016/j.tips.2017.06.003>
393 PMID: 28668224.
- 394 **30.** Hargreaves P, Daoudlarian D, Theron M, Kolb FA, Manchester Young M, Reis B, et al. Differential
395 effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren

- 396 syndrome. *Arthritis Res Ther.* 2019; 21(1): 175. Epub 20190718.
397 <https://doi.org/10.1186/s13075-019-1955-2> PMID: 31319889.
- 398 **31.** Shen XB, Chen X, Zhang ZY, Wu FF, Liu XH. Cathepsin C inhibitors as anti-inflammatory drug
399 discovery: Challenges and opportunities. *Eur J Med Chem.* 2021; 225: 113818. Epub 20210903.
400 <https://doi.org/10.1016/j.ejmech.2021.113818> PMID: 34492551.
- 401 **32.** Bouras M, Asehnoune K, Roquilly A. Immune modulation after traumatic brain injury. *Front Med*
402 (Lausanne). 2022; 9: 995044. Epub 20221201. <https://doi.org/10.3389/fmed.2022.995044> PMID:
403 36530909.
- 404 **33.** Nakanishi H. Microglial cathepsin B as a key driver of inflammatory brain diseases and brain
405 aging. *Neural Regen Res.* 2020; 15(1): 25-29. <https://doi.org/10.4103/1673-5374.264444> PMID:
406 31535638.
- 407 **34.** Senjor E, Kos J, Nanut MP. Cysteine Cathepsins as Therapeutic Targets in Immune Regulation and
408 Immune Disorders. *Biomedicines.* 2023; 11(2). Epub 20230207.
409 <https://doi.org/10.3390/biomedicines11020476> PMID: 36831012.
- 410 **35.** Randow F, MacMicking JD, James LC. Cellular self-defense: how cell-autonomous immunity
411 protects against pathogens. *Science.* 2013; 340(6133): 701-706.
412 <https://doi.org/10.1126/science.1233028> PMID: 23661752.
- 413 **36.** Anes E, Pires D, Mandal M, Azevedo-Pereira JM. Spatial localization of cathepsins: Implications in
414 immune activation and resolution during infections. *Front Immunol.* 2022; 13: 955407. Epub
415 20220803. <https://doi.org/10.3389/fimmu.2022.955407> PMID: 35990632.
- 416 **37.** Reinheckel T, Tholen M. Low-level lysosomal membrane permeabilization for limited release and
417 sublethal functions of cathepsin proteases in the cytosol and nucleus. *FEBS Open Bio.* 2022; 12(4):
418 694-707. Epub 20220309. <https://doi.org/10.1002/2211-5463.13385> PMID: 35203107.
- 419 **38.** Okada R, Zhang X, Harada Y, Wu Z, Nakanishi H. Cathepsin H deficiency in mice induces excess
420 Th1 cell activation and early-onset of EAE though impairment of toll-like receptor 3 cascade. *Inflamm*
421 *Res.* 2018; 67(5): 371-374. Epub 20180222. <https://doi.org/10.1007/s00011-018-1136-9> PMID:
422 29470604.
- 423 **39.** McNamara NB, Munro DAD, Bestard-Cuche N, Uyeda A, Bogie JFJ, Hoffmann A, et al. Microglia
424 regulate central nervous system myelin growth and integrity. *Nature.* 2023; 613(7942): 120-129. Epub
425 20221214. <https://doi.org/10.1038/s41586-022-05534-y> PMID: 36517604.
- 426 **40.** Ni J, Wu Z, Meng J, Saito T, Saido TC, Qing H, et al. An impaired intrinsic microglial clock system
427 induces neuroinflammatory alterations in the early stage of amyloid precursor protein knock-in
428 mouse brain. *J Neuroinflammation.* 2019; 16(1): 173. Epub 20190830.
429 <https://doi.org/10.1186/s12974-019-1562-9> PMID: 31470863.
- 430 **41.** Fan K, Li D, Zhang Y, Han C, Liang J, Hou C, et al. The induction of neuronal death by up-regulated
431 microglial cathepsin H in LPS-induced neuroinflammation. *J Neuroinflammation.* 2015; 12: 54. Epub
432 20150319. <https://doi.org/10.1186/s12974-015-0268-x> PMID: 25889123.
- 433 **42.** Ni J, Zhao J, Zhang X, Reinheckel T, Turk V, Nakanishi H. Cathepsin H deficiency decreases
434 hypoxia-ischemia-induced hippocampal atrophy in neonatal mice through attenuated TLR3/IFN- β
435 signaling. *J Neuroinflammation.* 2021; 18(1): 176. Epub 20210810.
436 <https://doi.org/10.1186/s12974-021-02227-7> PMID: 34376208.
- 437 **43.** Harada Y, Zhang J, Imari K, Yamasaki R, Ni J, Wu Z, et al. Cathepsin E in neutrophils contributes to
438 the generation of neuropathic pain in experimental autoimmune encephalomyelitis. *Pain.* 2019;
439 160(9): 2050-2062. <https://doi.org/10.1097/j.pain.0000000000001596> PMID: 31095099.

- 440 **44.** Chlabicz M, Gacko M, Worowska A, Lapiński R. Cathepsin E (EC 3.4.23.34)--a review. *Folia*
441 *Histochem Cytobiol.* 2011; 49(4): 547-557. <https://doi.org/10.5603/fhc.2011.0078> PMID: 22252749.
- 442 **45.** Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, et al. P2X4
443 receptors induced in spinal microglia gate tactile allodynia after nerve injury. *Nature.* 2003; 424(6950):
444 778-783. <https://doi.org/10.1038/nature01786> PMID: 12917686.
- 445 **46.** Nakanishi H. Microglial functions and proteases. *Mol Neurobiol.* 2003; 27(2): 163-176.
446 <https://doi.org/10.1385/mn:27:2:163> PMID: 12777686.
- 447 **47.** Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis--prevalence and clinical
448 characteristics. *Eur J Pain.* 2005; 9(5): 531-542. Epub 20041222.
449 <https://doi.org/10.1016/j.ejpain.2004.11.005> PMID: 16139182.
- 450 **48.** Ansari MA, Nadeem A, Alshammari MA, Attia SM, Bakheet SA, Khan MR, et al. Cathepsin B
451 inhibitor alleviates Th1, Th17, and Th22 transcription factor signaling dysregulation in experimental
452 autoimmune encephalomyelitis. *Exp Neurol.* 2022; 351: 113997. Epub 20220202.
453 <https://doi.org/10.1016/j.expneurol.2022.113997> PMID: 35122866.
- 454





Figure 1



medRxiv preprint doi: <https://doi.org/10.1101/2024.09.05.24313125>; this version posted September 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 2



Figure 3







Figure 4